• <em>TTN</em>-related hereditary myopathy with early respiratory failure presented with elevated hemoglobin initially: A case report and literature review
• ⁵¹Cr Red Blood Cells in the Study of Hematologic Disease: A Historical Review
• A 27-Year-Old Female With JAK2 Mutation: A Case of Budd-Chiari Syndrome Secondary to Prolonged Oral Contraceptive Pill Use
• A case report and literature review of IgA nephropathy presenting as nephrotic syndrome in polycythemia vera
• A lasso and random forest model using flow cytometry data identifies primary myelofibrosis
• A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
• A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery
• Acute myocardial infarction and polycythemia rubra vera: The double effect of treatment with hydroxyurea
• Acute upper gastrointestinal bleeding due to portal hypertension in a patient with primary myelofibrosis: A case report
• ADAMTS13, von Willebrand Factor, Platelet Microparticles, Factor VIII, and Impact of Somatic Mutations in the Pathogenesis of Splanchnic Vein Thrombosis Associated with BCR-ABL-Negative Myeloproliferative Neoplasms
• Advancements and Future Directions in Polycythemia Vera Research: A Bibliometric Analysis
• Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision Medicine
• Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature
• An Unusual Case of Extramedullary Hematopoiesis in the Right Kidney
• Analysis of risk factors for venous thromboembolism in patients with polycythemia vera and establishment of a prediction model
• Assessment of Total Antioxidant Capacity, 8-Hydroxy-2'-deoxy-guanosine, the Genetic Landscape, and Their Associations in <em>BCR::ABL-1</em>-Negative Chronic and Blast Phase Myeloproliferative Neoplasms
• Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis
• Being John Plasma Volumovich, pecularities of plasma volume estimation in patients with polycythemia vera
• Bibliometric analysis of worldwide research on Polycythemia Vera in the 21st century
• Clinical and Economic Implications of Hydroxyurea Intolerance in Polycythemia Vera in Routine Clinical Practice
• Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
• Clinical Insights and Dermatological Recommendations for Non-Melanoma Skin Cancers (NMSCs) in Long-Term Hydroxyurea (HU) Therapy
• Clinical methemoglobinemia secondary to administration of hydroxyurea at therapeutic doses in a dog
• Combination Therapy with Ruxolitinib and Pegylated Interferon-alpha2a in Newly Diagnosed Patients with Polycythemia Vera
• Comparison of the crystal structures of the JAK1/2 inhibitor ruxolitinib and its hydrate and phosphate
• Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians
• Conventional Cytogenetic Analysis and Array CGH + SNP Identify Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis Patients Who Are at Risk for Disease Progression
• Diagnostic Evaluation of Polycythemia Vera at High Altitude
• Direct and indirect costs for patients with myeloproliferative neoplasms
• Disappearance of a chromosomal abnormality in a young patient with polycythemia vera treated with ropeginterferon alfa-2b
• Disseminated cerebral cryptococcosis after silent West Nile virus infection in a patient with polycythemia vera: A case report and review of the literature
• Disseminated tuberculosis mimicking pleural mesothelioma in a polycythemia vera patient treated with ruxolitinib
• Distal Internal Carotid Artery Thrombus in Polycythemia Vera
• Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment
• Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b
• Equitable access to polycythemia vera treatments: addressing reimbursement disparities in Europe
• Erythrocytosis and CKD
• Erythrocytosis and CKD: A Review
• Erythrocytosis: Diagnosis and investigation
• Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis
• Exploring hematological alterations and genetics linked to SNV rs10974944 in myeloproliferative neoplasms among Amazon patients
• Givinostat: First Approval
• Hemangioblastoma: An Uncommon Cause of Polycythemia in a Child
• Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
• High red cell mass and high plasma volume are independently associated with thrombotic risk in polycythemia vera
• Histopathological Confirmed Polycythemia Vera with Transformation to Myelofibrosis Depicted on [(18)F]FDG PET/CT
• How I Treat Low-risk Polycythemia Vera Patients who Require Cytoreduction
• HSR24-156: Treatment Patterns and Blood Count Control in 10,112 Patients With Polycythemia Vera Managed at Community Practices in the United States
• Immunophenotype of myeloid granulocytes in Chinese patients with BCR::ABL1-negative myeloproliferative neoplasms
• Liver and spleen shear-wave elastography in the diagnosis and severity staging of myeloproliferative diseases and myelofibrosis
• Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment
• Miliary TB and COVID-19 Coinfection in a Patient With a History of Post-polycythemia Vera Myelofibrosis Treated With Ruxolitinib: A Case Report
• Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature
• Myeloproliferative Neoplasms Transcriptome Reveals Pro-Inflammatory Signature and Enrichment in Peripheral Blood Monocyte-Related Genes
• Myocardial infarction in young individual: A case report of polycythemia vera-induced acute inferior wall myocardial infarction
• Noninfectious Ascites Neutrophilia in a Patient With Polycythemia Vera
• Novel germline JAK2^R715T mutation causing PV-like erythrocytosis in 3 generations. Amelioration by Ropeg-Interferon
• Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms
• Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study
• Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis
• Polycythemia vera and essential thrombocythemia of intermediate-age: A real-life, multicenter analysis of first-line treatment approach
• Polycythemia vera and noncirrhotic portal hypertension diagnosed during pregnancy
• Polycythemia Vera Masked by Megaloblastic Anemia
• Polycythemia Vera Presenting As Acute Non-hemorrhagic Infarction and Chronic Bleed: Deception Between the Lines
• Polycythemia vera: past, present and future
• Post polycythemia vera myelofibrosis with myelodysplastic-like progression in a patient with chronic lymphocytic leukemia
• Post-polycythemia vera myelofibrosis with myelodysplastic-like progression in a patient with chronic lymphocytic leukemia
• Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis
• Prevalence and clinicopathological features of driver gene mutations profile in BCR: ABL1 negative classical myeloproliferative neoplasm-A single-center study from North India
• Primary polycythaemia: A neglected risk factor
• Real-life use of ropeg-interferon alpha2b in polycythemia vera: patient selection and clinical outcomes
• Real-World Electronic Medical Records Data Identify Risk Factors for Myelofibrosis and Can Be Used to Validate Established Prognostic Scores
• Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
• Recent findings and advances in treatment of myeloproliferative neoplasms
• Relationship between amide ratio assessed by Fourier-transform infrared spectroscopy: A biomarker candidate for polycythemia vera disease
• Relationship between DTA Mutations and Thromboembolism in Patients with Myeloproliferative Neoplasms
• Retinal Vessel Analysis and Microvascular Abnormalities in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
• Risk factors for ischemic stroke in patients with Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms
• Ruxolitinib associated psoas muscle tuberculosis abscess in a primary myelofibrosis woman: A case report and literature review
• Secondary Solid Cancers Among Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Multicenter Study
• Spinal extramedullary hematopoiesis mimicking an epidural tumor in a patient with high-risk polycythemia vera: illustrative case
• Systemic Inflammatory Index in Polycythemia Vera and Its Prognostic Implications
• The assessment of health-related quality of life in patients with polycythemia vera
• The Burden of symptoms and Quality of life of Filipino patients with Myeloproliferative neoplasm: A Multicenter Cross-sectional survey
• The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms
• The evolving landscape of polycythemia vera therapies
• The personal impact of living with a myeloproliferative neoplasm
• The Systemic Inflammation Index: A New Candidate Minor Criterion in the Diagnosis of Polycythemia Vera
• Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Myeloproliferative Neoplasms
• Trans-splenic Sharp Recanalization, Extra-Anatomic Portal Vein Reconstruction, and Intrahepatic Portosystemic Shunt creation for the Treatment of Portal Hypertension in a Patient with Polycythemia Vera and JAK2 Mutation
• Translation, Cultural Adaptation, and Validation into Romanian of the Myeloproliferative Neoplasm Symptom Assessment Form-Total Symptom Score (MPN-SAF TSS or MPN-10) Questionnaire
• Treatment of myelofibrosis with refractory anemia with luspatercept: a multicenter Chinese study
• Treatment outcome and germline predictive factors of ropeginterferon alpha-2b in myeloproliferative neoplasm patients
• Treatment with ropeginterferon alfa-2b in patients with hydroxyurea resistant or intolerant polycythemia vera in South Korea: one-year results from a phase 2 study
• Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean?
• Two Novel Genetic Variants Involved in the Oxygen Sensing Pathway in JAK2-unmutated Erythrocytosis
• Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms
• Unusual progression of polycythemia vera
• Venous Stasis Ulceration due to Massive Splenomegaly Causing Iliac Vein Compression From Secondary Myelofibrosis
• What are the future prospects for polycythemia vera pharmacotherapies for patients with hydroxyurea resistance?